OXFORD, England--(BUSINESS WIRE)--Midatech Group Ltd., a global leader and centre of excellence for the design, development, synthesis and manufacture of nanomedicines, today announced the expansion of its agreement with Monosol Rx (Warren, NJ) to develop nanoparticle-based proteins and peptides for therapeutic delivery using pharmaceutical films. Under the terms of the expanded agreement, Monosol Rx has made an equity investment in Midatech and Keith Kendall, Executive Vice President and Chief Financial Officer of MonoSol Rx, will join the Midatech Board of Directors.
